MedPath

Phase II study of Weekly Paclitaxel+Weekly Carboplatin for Platinum/Taxan sensitive recurrent mullerian carcinoma

Phase 2
Recruiting
Conditions
Platinum/Taxan sensitive recurrent mullerian carcinoma
Registration Number
JPRN-UMIN000003476
Lead Sponsor
Japan Kanto Tumor Board(JKTB)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
65
Inclusion Criteria

Not provided

Exclusion Criteria

1.Progression free interval<6months 2.Prior chemotherapy>2regimen 3.Pleural effusion need to continued drainage. 4.Evidense of severe or uncontrolled cardiac disease. 5.Hystory of myocardial infarction within 6months. 6.Hystory of cirrhosis or active hepatitis. 7.Severe plumonary disease(interstitial pneumonia,pulmonary fibrosis,)8.Gastrointestinal bleeding that requires iteration transfusion. 9.Serius psychological disease. 10.Uncontrolled diabetes. 11.Bowel obstruction. 12.Infection with fever. 13.Active double carcinoma. 14.Symptomatic brain metastasis. 15.Accute inflammatory desease. 16.Sevre peripheral neuropathy. 17.Patients with any history of serious drug reactions 18.History of hyper sensitivity to polyoxyethylene castor oil(ChremophorEL) or contained castor oil(vitamin injection) 19.Pregnant or lactating woman. 20.Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath